- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Genflow Biosciences PLC Announces Temporary Suspension | 202 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| Mi | Genflow Biosciences - Temporary Suspension | 2 | RNS | ||
| Mi | Official List - Suspension - GENFLOW BIOSCIENCES PLC | 2 | RNS | ||
| Di | Genflow Biosciences PLC Announces Total Voting Rights | 133 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| Di | Genflow Biosciences - Total Voting Rights | 1 | RNS | ||
| 10.04. | Genflow Biosciences PLC Announces Notification of Major Holdings | 41 | ACCESSWIRE | LONDON, UK / ACCESSWIRE / April 10, 2024 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason for... ► Artikel lesen | |
| 09.04. | Genflow Biosciences PLC Announces Notification of Major Holdings - 2 | 173 | ACCESSWIRE | LONDON, UK / ACCESSWIRE / April 9, 2024 / Genflow Biosciences PLC Announces Notification of Major Holdings - 2:TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer... ► Artikel lesen | |
| 09.04. | Genflow Biosciences PLC Announces Notification of Major Holdings - 1 | 177 | ACCESSWIRE | LONDON, UK / ACCESSWIRE / April 9, 2024 / Genflow Biosciences PLC (LSE:GENF)(OTCQB:GENFF)TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES... ► Artikel lesen | |
| 09.04. | Genflow Biosciences - NOTIFICATION OF MAJOR HOLDINGS | 1 | RNS | ||
| 04.04. | Genflow Biosciences PLC Announces Successful Placing and Subscription | 129 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 04.04. | Genflow Biosciences - Successful Placing and Subscription | - | RNS | ||
| 21.03. | Genflow confirms publication of European patent for SIRT6 | 1 | Alliance News | ||
| 21.03. | Genflow Biosciences PLC Announces Notification of Major Holdings | 209 | ACCESSWIRE | LONDON, UK / ACCESSWIRE / March 21, 2024 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason for... ► Artikel lesen | |
| 21.03. | Genflow Biosciences PLC Announces Publication of a Key European Patent | 222 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 21.03. | Genflow Biosciences - NOTIFICATION OF MAJOR HOLDINGS | 1 | RNS | ||
| 21.03. | Genflow Biosciences - Publication of a Key European Patent | 1 | RNS | ||
| 01.02. | TRADING UPDATES: Genflow wins new research grants; Seeen margin rises | 1 | Alliance News | ||
| 01.02. | Genflow Biosciences PLC: Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024 | 225 | GlobeNewswire (Europe) | Genflow Biosciences Plc ("Genflow" or "the Company") LONDON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The Company (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing... ► Artikel lesen | |
| 01.02. | Genflow Biosciences - Highlights and Key Priorities | - | RNS | ||
| 18.01. | Genflow secures grants for ageing research programs | 2 | Investing.com |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 46,840 | +0,32 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| AVIDITY BIOSCIENCES | 25,800 | +6,92 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| KEROS THERAPEUTICS | 57,72 | 0,00 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
| IMMUNOVANT | 28,520 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
| ARVINAS | 32,480 | +2,23 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 36,240 | +7,95 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting | New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session Nello Mainolfi, Founder, President... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,740 | +2,45 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| JANUX THERAPEUTICS | 58,19 | +2,09 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| VERA THERAPEUTICS | 42,310 | +7,09 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,340 | 0,00 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
| COGENT BIOSCIENCES | 6,910 | +6,31 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor | WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 28,100 | +4,07 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| CABALETTA BIO | 12,410 | 0,00 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,830 | +2,18 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| NUVALENT | 70,65 | +2,57 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +9,52 % bei einem Aktienkurs von 0,023 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
